Priority review of VAXNEUVANCE™ for kids 6 weeks to 17 years accepted by FDA
The US Food and Drug Administration has accepted a Priority Review of the pneumococcal 15-valent conjugate vaccine VAXNEUVANCE™ in children aged 17 years and younger.
The US Food and Drug Admistration (FDA) has accepted a Priority Review from Merck for a supplemental Biologics License Application for the company’s pneumococcal 15-valent conjugate vaccine to prevent invasive pneumococcal disease in children aged 6 weeks to 17 years.1 The target action date set by the FDA is April 1, 2022.
The supplemental application is buoyed by results from Phase 2/3 clinical trials in the pediatric population. The studies support using the vaccine for not only young patients, but those who are increased risk of pneumococcal disease like children with sickle cell disease. Furthermore, the data indicate that the vaccine could potentially be used in a mixed dose regimen with infants who had received an initial disease of a 13-valent vaccine as well for catch-up vaccinations for older children who were either vaccine-naïve or had either received a partial or full schedule on pneumococcal vaccines with fewer serotypes.
The serotypes covered by the vaccine include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F, of which 3: 22F, 33F and 3 are responsible for more than 25% of all cases of invasive pneumococcal disease in children aged younger than 5 years. It is currently approved for adults aged 18 years and older.
Reference
1. Merck. US FDA accepts for priority review the supplemental biologics license application for Merck’s VAXNEUVANCE™ (pneumococcal 15-valent conjugate Vaccine) for use in infants and children. Published December 1, 2021. Accessed December 1, 2021. https://www.merck.com/news/u-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-mercks-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children/
Are you administering the correct dose of Moderna’s COVID-19 vaccine?
November 6th 2023The FDA was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.
The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants
April 2nd 2022Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
RSV: 1 year post-tripledemic emergency department update
October 22nd 2023Steven Selbst, MD, provides a quick update on what he has noticed in his hospital when it comes to RSV-associated emergency department visits and how they compare to this time last year, during the "tripledemic." This interview was conducted at the 2023 American Academy of Pediatrics National Conference and Exhibition in Washington DC.
